Azacitidine: all 480 studies that test it
Page 5 of 5. Open to participants first (142), then studies with results posted, then the rest; newest registration first within each.
- Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDSStatus unknownNCT02124174Phase 2
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1
- Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02038816Phase 2
- Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedNCT02018926Phase 1/2
- Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.CompletedNCT02017457Phase 2
- Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerCompletedNCT02009436Phase 1
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
- Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic SyndromesCompletedNCT01913951Phase 1
- Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryTerminatedNCT01886573Phase 1
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1
- Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine TherapyCompletedNCT01828346Phase 1/2
- Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AMLTerminatedNCT01794169Phase 2
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
- A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDSStatus unknownNCT01718366Phase 1/2
- 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic SyndromeStatus unknownNCT01652781Phase 2
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
- The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).Status unknownNCT01556477Phase 2
- VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT01541280Phase 2
- A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and LiposarcomaCompletedNCT01537744Phase 1
- A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for ThrombocytopeniaCompletedNCT01488565Phase 2
- Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)CompletedNCT01462578Phase 2
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 1
- Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
- Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal CancerCompletedNCT01386346Phase 1
- Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent AnaemiaCompletedNCT01338337Phase 2
- Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic SyndromesWithdrawnNCT01324960Phase 1/2
- Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT01305460Phase 1/2
- Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic SyndromesCompletedNCT01305135Phase 1/2
- Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)CompletedNCT01301820Phase 2
- Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By SurgeryWithdrawnNCT01292083Not applicable
- Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1
- Azacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01235117Phase 2
- Study of Grifola Frondosa (Maitake), Azacitidine, and LenalidomideTerminatedNCT01200004Phase 1
- Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With AzacitidineCompletedNCT01180322Phase 2
- Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic CancerTerminatedNCT01167816Phase 1
- Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) PatientsCompletedNCT01152346Phase 1
- Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01129180Phase 1
- ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic MalignanciesCompletedNCT01110473Phase 1
- ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)WithdrawnNCT01067274Phase 3
- Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic SyndromeStatus unknownNCT01053806Phase 2
- Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01048034Phase 2
- Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum TherapyCompletedNCT01039155Phase 1
- A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor MalignanciesCompletedNCT00996515Phase 1
- Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
- Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesCompletedNCT00915785Phase 2
- Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00915252Phase 2
- MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
- Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck CancerTerminatedNCT00901537Phase 1
- 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)CompletedNCT00897130Phase 2
- Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian CancerWithdrawnNCT00842582Phase 1
- Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationCompletedNCT00795548Phase 2
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With AzacitidineCompletedNCT00741234Phase 1
- Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive ChemotherapyCompletedNCT00739388Phase 2
- Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyStatus unknownNCT00728520Phase 2
- Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)Status unknownNCT00704704Phase 2
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2
- Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian CancerCompletedNCT00529022Phase 1
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
- Azacytidine and Valproic Acid in Patients With Advanced CancersCompletedNCT00496444Phase 1
- SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic SyndromeTerminatedNCT00495547Phase 2
- A Phase II Study of Maintenance With Azacitidine in MDS PatientsTerminatedNCT00446303Phase 2
- Study of Azacitidine to Treat Relapsed or Refractory Multiple MyelomaTerminatedNCT00412919Phase 2
- Azacitidine and Interferon Alfa in Treating Patients With Metastatic MelanomaCompletedNCT00398450Phase 1
- Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/2
- Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)CompletedNCT00350818Phase 1
- Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell LymphomaActive, not recruitingNCT00336063Phase 1
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00234000Phase 1
- Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaTerminatedNCT00118196Phase 2
- MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
- Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
- 5-Azacytidine and Phenylbutyrate to Treat Severe ThalassemiaCompletedNCT00005934Phase 2
- Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00005639Phase 1
- Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic SyndromeCompletedNCT00005598Phase 2
- Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00004871Phase 1
- Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid CancerCompletedNCT00004062Phase 1